Book your standgotocphi.com/jp19Big Sight Exhibition Center Tokyo, Japan
18-20 March 2019
of CPhI Japan visitors found new partners for future collaboration*
* 2018 post show survey
20,000+pharma professionals
From 60+ Countries
5 eventsin 1 location
3 daysof business, learning &
networking opportunities
“Attending CPhI Japan was a good chance to get in contact with Japanese companies and to understand the Japanese pharma industry and trends. We are looking forward to attending this wonderful exhibition again and to exchange our experience with local Japanese companies.”Andrea SalvadoriSales Area Manager PQE
gotocphi.com/jp19 For more information contact: [email protected]
“As an integrated pharma company, CPhI Japan is an important and effective platform for us to meet existing and new partners, but also to
raise our profile and brand awareness.”Silke Oeschger
Marketing and Communication Manager Dr. Reddy’s Laboratories
87%
Facts & figuresof the 2018 show550 exhibitors from 32 countriesand 19,509 visitors from 67 countries!
Visitor business categories
12.4% Trading Company
33% Pharmaceutical manufacturing/Pharmaceutical contract manufacturing
22.6%
32% Others
Positions - Pharmaceutical manufacturing/ Pharmaceutical contract manufacturing
Top 10 visitor countries
Fine Chemical/ API/ Intermediates Manufacturing
Positions - Fine chemical manufacturing/ Intermediate manufacturing/ API manufacturing
36.5%
12%
10.2%
10.7%
4.9%
25.7%
Research/Development
Quality Control/Production
Purchasing/Procurement/Logistic
Management
Marketing
Other
Primary purpose of visitLooking for new suppliers, ingredients & services 44%
Attending conferences and exhibitor presentations10%
Maintaining business relationships10%
Others4%
31.2%
8.6%
8.3%
6.8%
6.1%
39%
Obtaining market / product information32%
1. Japan 3. South Korea2. China 4. India
5. Taiwan 6. Germany 7. Spain
10. Italy
Research/Development
Quality Control/Production
Purchasing/Procurement/Logistic
Management
Marketing
Other
8. USA
9. Vietnam
For more on market trends visit www.cphi.com/japan
Entering the next stage as a global hub for drug developmentJapan has joined the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Cooperation Scheme (PIC/S). This enables overseas suppliers to synchronise with Japanese pharmaceutical manufacturers regarding manufacturing and quality control. In addition, Japan’s pharmaceutical industry will become more international as well as easier for foreign suppliers to enter the Japanese market!
1. Japan is the 3rd largest pharma market in the world
2. The Japanese pharma market is expected to reach a value of $105bn by 2021 and $109bn by 2026
3. The global biopharmaceutical market is forecasted to reach $306bn by 2020. Asia-Pacific is forecasted to emerge as the fastest growing market with a CAGR of 12.2%
Japan has a high dependency rate for APIson overseas suppliers of generic drugs
Imported
of APIs are imported from outside Japan for Generic Drug
Manufacturing in Japan
51.2% - 57.8%
Top 6 API suppliers in two categories*
*Value based
1. Korea 31% 2. China 12.3% 3. Spain 9.9% 4. Italy 8.9% 5. Hungary 8.4% 6. India 7.2%
1. India 30% 2. Korea 26% 3. China 24.1% 4. Germany 9.6% 5. Italy 1.4% 6. Taiwan 1.4%
For APIs which are used without additional purification/reprocess
For APIs which required additional purification/reprocess
Reference: The Ministry of Health, Labour and Welfare’s Generic Drug Report conducted by Mitsubishi UFJ Research and Consulting Co., Ltd.
Key factors to choose overseas API suppliers for generic drugs manufacturing in Japan
0 20 40 60 80 100
1234
56
78
86.7%81.6%
67.7%64.6%
57.6%55.7%55.4%
42.4%
1. Meet Japan’s GMP standard2. Maintain a stable supply3. Competitive price4. Keep delivery date5. Quality control capability6. Management stability7. History with Japanese companies8. Social and political stability
Reference: The Ministry of Health, Labour and Welfare’s Generic Drug Report conducted by Mitsubishi UFJ Research and Consulting Co., Ltd.
Pharmaceutical Market Forecast(2017 - 2021)
Pharmaceutical market growth
Ageing PopulationJapan's ageing population will further drive demand for pharmaceutical products. By 2030, the pensionable population as a percentage of the total will grow to 31.2%, up from 25.8% in 2014.
Liberalisation of Over-The-Counter Medicines
The liberalisation of Over-The-Counter medicines and the allowance of sales of over-the-counter (OTC) drugs online serve to boost pharmaceutical sales. 99.8% of OTC drugs are now eligible for sale online (more than 11,000 drugs).
For more on market trends visit www.cphi.com/japan
Why Japan?
2017 2018 2019 2020 2021
105
100
95
US$bnin Sales
Reference: BMI
101.
853
103.
065 10
4.07
0
105.
147
102.
016
Research & DevelopmentJapan’s R&D remains at the forefront of the global pharmaceutical industry. This is a confluence of both the attractiveness of the country’s medicine market as well as the strength of local research institutions in the country. In biomedical R&D spending, Japan is the third largest in the world, accounting for approximately 10% of the total expenditure.
Exhibitor profile:Exhibitors at CPhI Japan are active in a range of business sectors, including:
Exhibitor profile of co-located shows:Exhibitors at ICSE, P-MEC, InnoPack and BioPh Japan are active in a range of business sectors, including:
ContractServices
Technology& Machinery
LaboratoryEquipment
Networking & learning at the show
Exhibitor Showcase Educate the industry about your products, services, new launches, innovations and news during a 30 minute presentation attended by visitors, press and fellow exhibitors. Create a buzz around your news at the show and benefit: • Maximise exposure before, during and after the event• Drive attendees to your stand• Generate new leads
Seminars Seminars on trending industry topics give valuable insight into the Japanese pharma industry. As the industry is undergoing change, be sure to attend and gain competitive advantage. Seminars included sessions by the Ministry of Health, Labour and Welfare, leading international and domestic pharmaceutical companies and prestigious universities.
Business Matchmaking Programme The “Business Matchmaking Programme” is a gateway for exhibitors to meet potential buyers. Exhibitors can find visitor enquiries on products or services they are looking for. You can contact the visitors whom you are interested in by making appointments. All exhibitors are welcome to participate FREE of charge!
CPhI Online Enhance online exposure of your company and products on CPhI Online. Stay connected with buyers before and after the show. With 42,000+ unique visitors per month, CPhI Online is a pharma sourcing directory that allows you to:• Generate leads• Increase brand awareness• Stay updated on pharma industry news and trends
Visitors’ top 3 job positions
41%
An event that is full of potential to expand existing business, explore new markets, learn the latest trends in the industry and to learn about the business culture.
Ashish TrivediDishman Pharmaceuticals and Chemicals Limited
“ “Packaging,
Drug delivery
Biopharmaceuticals
Non-Management Chugai, Otsuka, Nichi-Iko, Eisai, Otsuka
Ingredients Finished Formulation
%38Management Shionogi, Mitsubishi Pharma. Teijin,Taisho, Pfizer Japan
%
19CEO/Chairman/Vice President/Director Takeda, Astellas, Daiichi Sankyo, Mochida, Kyowa Hakko
gotocphi.com/jp19 For more information contact: [email protected]